Emerging Poly‐Agonists for Obesity and Type 2 Diabetes
暂无分享,去创建一个
[1] H. Berthoud,et al. Gut-Brain Cross-Talk in Metabolic Control , 2017, Cell.
[2] H. Fuchs,et al. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease , 2016, Cell.
[3] M. Roth,et al. Glucagon therapeutics: Dawn of a new era for diabetes care , 2016, Diabetes/metabolism research and reviews.
[4] M. Tschöp,et al. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. , 2016, Cell metabolism.
[5] R. Seeley,et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents , 2014, Nature Medicine.
[6] Bin Yang,et al. Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.
[7] D. Drucker,et al. Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.
[8] Bin Yang,et al. Targeted estrogen delivery reverses the metabolic syndrome , 2012, Nature Medicine.
[9] M. Christensen,et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.
[10] S. Woods,et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.